Notable Labs, Inc. announced its acquisition of VBL Therapeutics on February 23. Notable’s stockholders will receive newly issued ordinary shares and investors have committed an additional $10.3 million in a private placement to Notable, led by Builders VC, B Capital Group, Y Combinator, First Round Capital & Founders Fund.
Chardan Capital Markets LLC is serving as the exclusive financial advisor to VBL Therapeutics, and Goodwin Procter LLP and Horn & Co. are serving as legal counsel to VBL Therapeutics. JMP Securities LLC is serving as exclusive financial advisor for Notable and Wiggin and Dana LLP and Meitar are serving as legal counsel to Notable.
The combined company is expected to operate under the name Notable Labs, Ltd. with its shares listed on the Nasdaq under the ticker symbol “NTBL.” It will focus on the advancement of Notable’s proprietary Predictive Precision Medicines Platform and therapeutic pipeline that is focused on cancer patients with unmet medical needs.
Vascular Biogenics Ltd., operating as VBL Therapeutics, develops targeted therapies for immune-inflammatory diseases. VBL Therapeutics’ lead immunology product candidate, VB-601, is a targeted antibody for immune-inflammatory applications that has shown disease-modifying activity across multiple preclinical models including multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease. The company is based in Modi’in, Israel, and Pearl River, New York.
Notable Labs, Inc. is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform, Notable bio-simulates a cancer treatment and predicts whether a patient is likely to respond to that specific therapeutic.
According to data captured in the LevinPro HC database, this transaction represents the 33rd Biotechnology transaction of 2023. In the same time frame of January 1, 2022 through February 23, 2022, 19 Biotechnology acquisitions were reported.
